Archive for November 2012
Brilliantly introduced by Robin Neidorf, there is a white paper this month at Freepint that is worth reading . It explains how is could be risky for a company to rely only on free news service.
“Free sources of news are increasingly used in the enterprise as “good enough” for most purposes. However, there are times when “good enough” isn’t enough, and it’s essential for a researcher to know when those are… and to have the right tools to hand. (…)
Information professionals report to us that they know premium news providers offer better search, more targeted results, more flexible output options and a host of other features that save them and their client time. (…)
There are plenty of times when “good enough” is distinctly not enough.
Read the full story at:
Neidorf, Robin. News Diligence: When “Good Enough” Just Isn’t, Freepint, 28th of November 2012. Available from: http://web.freepint.com/go/features/69549
A nice presentation including disruptive features such as applications, etc.
If you cannot show the video above, go to:
In the latest issue of Research Information, David Stuart is wondering how researchers now can evaluate the impact of these new ways of publishing, including social channels.
One of the answer is Altmetrics, the growing application that you will find now in every science journals and databases (like Scopus for e.g.) and which measures popularity of an article on Facebook, Twitter, etc.
Use of this way to measure the research performance is still controversial (but still is Impact Factor 50 years after its beginning!) and “there is a long way to go before altmetrics fully answer any of the questions that are being raised by the new research environment“, says David.
However, altmetrics fast adoption shows that “research landscape is much more than journal articles, and there is a lot of value to be created by measuring the connections between the new types of publication“.
Stuart, David. Making metrics more relevant. Research Information, Dec. 2012/ Jan 2013. pp.13-16. available from: http://content.yudu.com/A1zwzg/RIDEC12JAN13/resources/13.htm
“Physicians are more likely to read the print version of new medical journals versus any type of digital version, including full digital reproductions, the publication’s website as well as tablet and smart phone applications, according to the Kantar Media Sources & Interactions Study, September 2012 – Medical/Surgical Edition.
The study reveals that 90% of doctors read the print version of current issues of medical journals, far more than the 48% reading journals digitally. Of all doctors surveyed, 98% read current issues of journals and 44% utilize two or more platforms for reading. (…)
Unsurprisingly, younger doctors are more inclined to be digital readers than their older colleagues. However, even among the youngest demographic, print is still the most-used platform for reading current issues of journals”.
Publishers and Advertisers Can’t Go 100% Digital If They Want to Reach Majority of Doctors. PharmaLive, November 2012, Available from: http://pharmalive.com/news/index.cfm?articleid=867937&categoryid=43
Europe PubMedCentral = 25 million abstracts from Medline + 2 million OA full-text articles + Agricola + biological Patents + thesis + clinical guidelines…
Unlike PubMed Central, Europe PMC provides a single point of access to not only full-text articles but additionally the abstracts available through PubMed. The Europe PMC interface also offers novel features and functionality, including links to other relevant content, integrated text and data mining tools and grant reporting services through Europe PMC plus.
It seems that Open Pharma is really gaining momentum in the industry, even with Big Pharma. Every week sees news showing Open innovation initiatives…
“Janssen Research & Development, LLC (Janssen R&D) today announced the establishment of a global cross-pharmaceutical Investigator Databank designed to improve efficiencies of industry-sponsored clinical trials. Merck and Eli Lilly and Company are the first two companies to join Janssen in this effort. The new Investigator Databank, established as part of this novel industry collaboration, will serve as a one-stop repository where key information about clinical trial sites, such as infrastructure and Good Clinical Practice (GCP) training records, is housed. This will allow participating pharmaceutical companies to reduce time-consuming and sometimes redundant administrative work involved in identifying appropriate clinical trial sites. ”
Janssen Research & Development Announces Establishment of Global Cross-Pharmaceutical Clinical Trial Investigator Databank. Drugs.com, 15 November 2012. Available from: http://www.drugs.com/news/janssen-research-amp-development-announces-establishment-global-cross-pharmaceutical-clinical-trial-41551.html